Amphion Innovations plc

Update on Polarean Imaging IPO

London and New York, 29 March 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc ("Polarean") will list on the AIM market of the London Stock Exchange today.

As previously announced, Polarean raised gross proceeds of £3 million by way of a conditional placing through its nominated adviser and broker, Northland Capital Partners Limited, and a conditional subscription.

The Admission will become effective at 8am today and shares will trade under the AIM symbol ‘POLX’. Polarean is expected to have a market capitalisation on admission of at least £11 million. Amphion has participated in the Placing and following Admission will remain the largest shareholder holding c. 17 million shares, equivalent to 23.2% of the enlarged Share Capital of Polarean.

For further information on Polarean’s listing, please see here: 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.